{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.5","upperLimit":"90.3","value":"72.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"The clinical benefit rate (CBR) was defined as Overall Response Rate (ORR) plus Minimal Response (MR) as defined by the European Group for Blood and Marrow Transplantation (EBMT) criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"The Cohort Safety Review Committee (CSRC) determined this dose as the recommended phase 2 dose (RP2D). Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.","id":"OG000","title":"Phase 2 300 mg 2/7 Schedule"}],"paramType":"NUMBER","populationDescription":"Safety Population","reportingStatus":"POSTED","timeFrame":"Screening: Day 14 to Day -1; During study: Day 1 up to 13.16 months","title":"Percentage of Participants Who Achieved a Clinical Benefit Response As Assessed by Investigator During Phase 2","type":"SECONDARY","unitOfMeasure":"percentage of participants"}